Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Gastro-enteropancreatic neuroendocrine tumor 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma in Situ 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

tivozanib 1grapiprant 1Tamsulosin 1Standard of Care 1Radiosurgery 1Practice Guidelines as Topic 1Palliative Care 1Nivolumab 1Multiparametric Magnetic Resonance Imaging 1Lycopene 1Gemcitabine 1Epirubicin 1Cystectomy 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Clinical Trials, Phase II as Topic × Genitourinary × Clear all
NCT04503265 2025-05-01

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

Phase 1/2 Recruiting
122 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡